Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Bucillamine

    Client Email Product

    Bucillamine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    7
    US DMFs Filed

    US DMFs Filed

    3
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    4
    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    1
    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    1
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    37
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Revive Submits Type C Meeting Request Package to FDA for trial of Bucillamine
    Revive Submits Type C Meeting Request Package to FDA for trial of Bucillamine

    https://www.globenewswire.com/news-release/2024/03/27/2853251/0/en/Revive-Therapeutics-Submits-Type-C-Meeting-Request-Package-to-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

    GLOBENEWSWIRE
    27 Mar 2024
    Share Share
    Revive To Submit Type C Meeting Request with FDA for Bucillamine to Treat COVID
    Revive To Submit Type C Meeting Request with FDA for Bucillamine to Treat COVID

    https://www.globenewswire.com/news-release/2024/03/19/2848420/0/en/Revive-Therapeutics-To-Submit-Type-C-Meeting-Request-with-FDA-for-Bucillamine-to-Treat-Long-COVID.html

    GLOBENEWSWIRE
    19 Mar 2024
    Share Share
    Revive Provides Update Evaluating Bucillamine for Nerve Agent Exposure
    Revive Provides Update Evaluating Bucillamine for Nerve Agent Exposure

    https://www.globenewswire.com//news-release/2024/01/16/2809707/0/en/Revive-Therapeutics-Provides-Update-Evaluating-Bucillamine-for-Nerve-Agent-Exposure-with-Defence-Research-and-Development-Canada.html

    GLOBENEWSWIRE
    16 Jan 2024
    Share Share
    Revive Completes Development of Lyophilized Formulation of Bucillamine
    Revive Completes Development of Lyophilized Formulation of Bucillamine

    https://www.globenewswire.com//news-release/2024/01/10/2806975/0/en/Revive-Therapeutics-Successfully-Completes-Development-of-a-Novel-Lyophilized-Formulation-of-Bucillamine.html

    GLOBENEWSWIRE
    10 Jan 2024
    Share Share
    Revive Therapeutics Collaborates with Attwill Medical Solutions
    Revive Therapeutics Collaborates with Attwill Medical Solutions

    https://www.globenewswire.com//news-release/2023/12/18/2797682/0/en/Revive-Therapeutics-Collaborates-with-Attwill-Medical-Solutions-for-the-Clinical-and-Commercial-Development-of-a-Novel-Lyophilized-Formulation-of-Bucillamine.html

    GLOBENEWSWIRE
    18 Dec 2023
    Share Share
    Revive Enters into Agreement with Defence R&D for Evaluating Bucillamine
    Revive Enters into Agreement with Defence R&D for Evaluating Bucillamine

    https://www.globenewswire.com//news-release/2023/10/17/2761367/0/en/Revive-Therapeutics-Enters-into-Agreement-with-Defence-Research-and-Development-Canada-for-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

    GLOBENEWSWIRE
    17 Oct 2023
    Share Share
    Revive Therapeutics Announces Filing of Patent for Bucillamine
    Revive Therapeutics Announces Filing of Patent for Bucillamine

    https://www.globenewswire.com/news-release/2023/07/28/2713021/0/en/Revive-Therapeutics-Announces-Filing-of-Patent-for-Bucillamine-in-the-Treatment-of-Exposure-to-Chemical-Warfare-Agents.html

    GLOBENEWSWIRE
    28 Jul 2023
    Share Share
    Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine
    Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine

    https://www.globenewswire.com/news-release/2023/05/30/2678239/0/en/Revive-Therapeutics-Provides-Update-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html

    GLOBENEWSWIRE
    30 May 2023
    Share Share
    Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine
    Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine

    https://www.globenewswire.com/news-release/2023/05/12/2667677/0/en/Revive-Therapeutics-Provides-Update-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html

    GLOBENEWSWIRE
    12 May 2023
    Share Share
    Revive Announces Data Safety Monitoring Board Meeting Pha3 Study of Bucillamine
    Revive Announces Data Safety Monitoring Board Meeting Pha3 Study of Bucillamine

    https://www.globenewswire.com/news-release/2023/05/02/2658886/0/en/Revive-Therapeutics-Announces-Data-Safety-Monitoring-Board-Meeting-Date-on-Phase-3-Clinical-Study-of-Bucillamine-in-the-Treatment-of-COVID-19.html

    GLOBENEWSWIRE
    02 May 2023
    Share Share
    Revive Provides Phase 3 Study for Bucillamine in the Treatment of COVID-19
    Revive Provides Phase 3 Study for Bucillamine in the Treatment of COVID-19

    https://www.globenewswire.com/news-release/2023/03/20/2630256/0/en/Revive-Therapeutics-Provides-Update-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html

    GLOBENEWSWIRE
    20 Mar 2023
    Share Share
    Revive Provides Update From Type C Meeting with FDA forfor Bucillamine
    Revive Provides Update From Type C Meeting with FDA forfor Bucillamine

    https://www.globenewswire.com/news-release/2023/03/08/2622940/0/en/Revive-Therapeutics-Provides-Update-From-Type-C-Meeting-with-FDA-for-Amended-Protocol-Agreement-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html

    GLOBENEWSWIRE
    08 Mar 2023
    Share Share
    Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
    Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

    https://www.globenewswire.com/news-release/2023/01/19/2592166/0/en/Revive-Therapeutics-Submits-Updated-Briefing-Package-in-Support-of-Upcoming-Type-C-Meeting-Granted-by-FDA-for-Amended-Protocol-Agreement-of-Phase-3-Clinical-Study-for-Bucillamine-i.html

    GLOBENEWSWIRE
    19 Jan 2023
    Share Share
    Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
    Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

    https://www.globenewswire.com/news-release/2023/01/12/2588205/0/en/Revive-Therapeutics-To-Submit-Updated-Briefing-Package-in-Support-of-Upcoming-Type-C-Meeting-Granted-by-FDA-for-Amended-Protocol-Agreement-of-Phase-3-Clinical-Study-for-Bucillamine.html

    GLOBENEWSWIRE
    12 Jan 2023
    Share Share
    Revive Therapeutics Announces Submission of Type C Meeting Request
    Revive Therapeutics Announces Submission of Type C Meeting Request

    https://www.globenewswire.com//news-release/2022/12/22/2578874/0/en/Revive-Therapeutics-Announces-Submission-of-Type-C-Meeting-Request-to-FDA-for-Amended-Protocol-Agreement-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html

    GLOBENEWSWIRE
    22 Dec 2022
    Share Share
    Revive Therapeutics Provides Update on Pha3 Clinical Trial for Bucillamine
    Revive Therapeutics Provides Update on Pha3 Clinical Trial for Bucillamine

    https://www.globenewswire.com/news-release/2022/10/06/2529697/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    06 Oct 2022
    Share Share
    Revive Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
    Revive Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2022/08/16/2498850/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    16 Aug 2022
    Share Share
    Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
    Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2022/07/25/2485232/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    25 Jul 2022
    Share Share
    Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
    Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2022/06/06/2457126/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    06 Jun 2022
    Share Share
    Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
    Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2022/05/16/2444105/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    16 May 2022
    Share Share
    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine
    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine

    https://www.globenewswire.com/news-release/2022/04/25/2428588/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    25 Apr 2022
    Share Share
    Revive Therapeutics Receives FDA ODD for Bucillamine
    Revive Therapeutics Receives FDA ODD for Bucillamine

    https://www.globenewswire.com/news-release/2022/02/15/2385731/0/en/Revive-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-Bucillamine-in-the-Prevention-of-Ischemia-Reperfusion-Injury-During-Liver-Transplantation.html

    GLOBENEWSWIRE
    15 Feb 2022
    Share Share
    Revive Tx Provides Update on Phase 3 Trial for Bucillamine in COVID-19
    Revive Tx Provides Update on Phase 3 Trial for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2022/01/19/2368970/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    19 Jan 2022
    Share Share
    Revive Clarifies Status of Phase 3 Clinical Trial for Bucillamine in COVID-19
    Revive Clarifies Status of Phase 3 Clinical Trial for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2022/01/06/2362848/0/en/Revive-Therapeutics-Clarifies-Status-of-Its-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    06 Jan 2022
    Share Share
    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine
    Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine

    https://www.globenewswire.com/news-release/2021/12/29/2359021/0/en/Revive-Therapeutics-Provides-Update-on-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    29 Dec 2021
    Share Share
    Revive Files for FDA Orphan Drug Designation for Bucillamine
    Revive Files for FDA Orphan Drug Designation for Bucillamine

    https://www.globenewswire.com/news-release/2021/11/23/2339614/0/en/Revive-Therapeutics-Files-for-FDA-Orphan-Drug-Designation-for-Bucillamine-in-the-Prevention-of-Ischemia-Reperfusion-Injury-During-Liver-Transplantation.html

    GLOBENEWSWIRE
    23 Nov 2021
    Share Share
    Revive Provides Update on FDA Phase 3Trial for Bucillamine in COVID-19
    Revive Provides Update on FDA Phase 3Trial for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2021/10/26/2320641/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    26 Oct 2021
    Share Share
    Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine
    Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine

    https://www.globenewswire.com/news-release/2021/06/08/2243655/0/en/Revive-Therapeutics-Partners-with-Supriya-to-Pursue-EUA-for-Bucillamine-to-Treat-COVID-in-India.html

    GLOBENEWSWIRE
    08 Jun 2021
    Share Share
    Revive Provides Update on FDA Phase 3 Clinical Trial for Bucillamine
    Revive Provides Update on FDA Phase 3 Clinical Trial for Bucillamine

    https://www.globenewswire.com/news-release/2020/12/23/2150036/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19-with-Plans-on-Emergency-Use-Access.html

    GLOBENEWSWIRE
    23 Dec 2020
    Share Share
    Revive Provides Update on FDA Phase 3 Clinical Trial for Bucillamine
    Revive Provides Update on FDA Phase 3 Clinical Trial for Bucillamine

    https://www.globenewswire.com/news-release/2020/12/23/2150036/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19-with-Plans-on-Emergency-Use-Access.html

    GLOBENEWSWIRE
    23 Dec 2020
    Share Share
    Revive Therapeutics Announces IRB Approval of US Expanded Access for Bucillamine
    Revive Therapeutics Announces IRB Approval of US Expanded Access for Bucillamine

    https://www.globenewswire.com/news-release/2020/09/16/2094472/0/en/Revive-Therapeutics-Announces-IRB-Approval-of-US-Expanded-Access-Treatment-Program-Compassionate-Use-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    16 Sep 2020
    Share Share
    Revive Therapeutics Announces IRB Approval for Bucillamine in COVID-19
    Revive Therapeutics Announces IRB Approval for Bucillamine in COVID-19

    https://www.globenewswire.com/news-release/2020/08/31/2086162/0/en/Revive-Therapeutics-Announces-IRB-Approval-for-Phase-3-Clinical-Trial-Protocol-for-Bucillamine-in-COVID-19.html

    GLOBENEWS WIRE
    31 Aug 2020
    Share Share
    Revive Announces Submission of IRB Approval for Ph3 Trial Protocol Bucillamine
    Revive Announces Submission of IRB Approval for Ph3 Trial Protocol Bucillamine

    https://www.globenewswire.com/news-release/2020/08/26/2084121/0/en/Revive-Therapeutics-Announces-Submission-of-IRB-Approval-for-Phase-3-Clinical-Trial-Protocol-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    26 Aug 2020
    Share Share
    Revive Therapeutics receives US FDA nod to begin phase 3 trial of Bucillamine
    Revive Therapeutics receives US FDA nod to begin phase 3 trial of Bucillamine

    http://www.pharmabiz.com/NewsDetails.aspx?aid=130561&sid=2

    PHARMABIZZ
    21 Aug 2020
    Share Share
    Revive Update Following U.S. FDA Approval of Ph3 Trial for Bucillamine
    Revive Update Following U.S. FDA Approval of Ph3 Trial for Bucillamine

    https://www.globenewswire.com/news-release/2020/08/05/2073326/0/en/Revive-Therapeutics-Update-Following-U-S-FDA-Approval-of-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    05 Aug 2020
    Share Share
    Revive Announces U.S. FDA Approval of Confirmatory PH3 Trial for Bucillamine
    Revive Announces U.S. FDA Approval of Confirmatory PH3 Trial for Bucillamine

    https://www.globenewswire.com/news-release/2020/07/31/2071110/0/en/Revive-Therapeutics-Announces-U-S-FDA-Approval-of-Confirmatory-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19.html

    GLOBENEWSWIRE
    31 Jul 2020
    Share Share
    Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request Health Canada
    Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request Health Canada

    https://www.globenewswire.com/news-release/2020/06/03/2043083/0/en/Revive-Therapeutics-Announces-Filing-of-a-Pre-CTA-Meeting-Request-with-Health-Canada-and-Update-on-U-S-FDA-IND-Filing-and-Phase-3-Clinical-Trial-Design-for-Bucillamine-in-the-Treat.html

    GLOBENEWSWIRE
    03 Jun 2020
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    View Presentation

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search